Tacrolimus Treatment for Refractory PRCA
Pure Red Cell Aplasia
About this trial
This is an interventional treatment trial for Pure Red Cell Aplasia focused on measuring tacrolimus, refractory pure red cell aplasia, prospective study
Eligibility Criteria
Inclusion Criteria:
Refractory pure red cell aplasia. 18-80 years old. No response or intolerant to first and second line therapies. Written informed consent.
Exclusion Criteria:
Other diseases which might cause hematological abnormalities. Response and well tolerate to first or second line therapy. Patients who are under 18-year-old or over 80-year-old. Pregnant or lactating. Patients unwilling to or unable to comply with the protocol.
Sites / Locations
- Peking Union Medical College HospitalRecruiting
Arms of the Study
Arm 1
Experimental
efficiency of tacrolimus on PRCA
A prospective research of the tacrolimus efficiency on refractory PRCA patients On refractory PRCA patients, tacrolimus was tried. Dosage: 1mg bid and tacrolimus trough targets were 5-10 ng/ml throughout the study. Medication time should last at least 6 months.